These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
101 related items for PubMed ID: 9642629
1. Final height in long-term primary hypothyroid children. Chiesa A, Gruñeiro de Papendieck L, Keselman A, Heinrich JJ, Bergadá C. J Pediatr Endocrinol Metab; 1998; 11(1):51-8. PubMed ID: 9642629 [Abstract] [Full Text] [Related]
2. Growth prognosis and growth after menarche in primary hypothyroidism. Pantsiouou S, Stanhope R, Uruena M, Preece MA, Grant DB. Arch Dis Child; 1991 Jul; 66(7):838-40. PubMed ID: 1863095 [Abstract] [Full Text] [Related]
4. Evaluation of central precocious puberty treatment with GnRH analogue at the Triangulo Mineiro Federal University (UFTM). Borges Mde F, Franciscon Pde M, Cambraia TC, Oliveira DM, Ferreira BP, Resende EA, Palhares HM. Arch Endocrinol Metab; 2015 Dec; 59(6):515-22. PubMed ID: 26421668 [Abstract] [Full Text] [Related]
5. Final height and body disproportion in thalassaemic boys and girls with spontaneous or induced puberty. Filosa A, Di Maio S, Baron I, Esposito G, Galati MG. Acta Paediatr; 2000 Nov; 89(11):1295-301. PubMed ID: 11106039 [Abstract] [Full Text] [Related]
6. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty. Paterson WF, McNeill E, Young D, Donaldson MD. Clin Endocrinol (Oxf); 2004 Nov; 61(5):626-34. PubMed ID: 15521967 [Abstract] [Full Text] [Related]
7. Factors predicting final height in early treated congenital hypothyroid patients. Delvecchio M, Salerno M, Acquafredda A, Zecchino C, Fico F, Manca F, Faienza MF, Cavallo L. Clin Endocrinol (Oxf); 2006 Nov; 65(5):693-7. PubMed ID: 17054475 [Abstract] [Full Text] [Related]
8. A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation. Kamp GA, Mul D, Waelkens JJ, Jansen M, Delemarre-van de Waal HA, Verhoeven-Wind L, Frölich M, Oostdijk W, Wit JM. J Clin Endocrinol Metab; 2001 Jul; 86(7):2969-75. PubMed ID: 11443153 [Abstract] [Full Text] [Related]
9. Treatment and disease effects on short-term growth and adult height in children and adolescents with 21-hydroxylase deficiency. Hauffa BP, Winter A, Stolecke H. Klin Padiatr; 1997 Jul; 209(2):71-7. PubMed ID: 9113619 [Abstract] [Full Text] [Related]
10. Growth and sexual maturation in children after kidney transplantation. van Diemen-Steenvoorde R, Donckerwolcke RA, Brackel H, Wolff ED, de Jong MC. J Pediatr; 1987 Mar; 110(3):351-6. PubMed ID: 3546648 [Abstract] [Full Text] [Related]
11. Final height after combined growth hormone and gonadotrophin-releasing hormone analogue therapy in short healthy children entering into normally timed puberty. Lanes R, Gunczler P. Clin Endocrinol (Oxf); 1998 Aug; 49(2):197-202. PubMed ID: 9828907 [Abstract] [Full Text] [Related]
12. The long-term effect of cyproterone acetate on growth in girls with idiopathic precocious puberty. Androcur Study Group in Japan. Kato K, Fujimoto M, Hibi I, Suwa S, Shimizu N. Eur J Pediatr; 1993 Apr; 152(4):297-300. PubMed ID: 8482275 [Abstract] [Full Text] [Related]
13. Non-classical 21-hydroxylase deficiency in infancy and childhood: the effect of time of initiation of therapy on puberty and final height. Weintrob N, Dickerman Z, Sprecher E, Galatzer A, Pertzelan A. Eur J Endocrinol; 1997 Feb; 136(2):188-95. PubMed ID: 9116914 [Abstract] [Full Text] [Related]
14. [Accuracy of the methods for height prediction in patients treated for congenital primary hypothyroidism]. Bueno Lozano G, Ruibal Francisco JL, Reverte Blanc F, Casado de Frías E. An Esp Pediatr; 1997 Dec; 47(6):595-600. PubMed ID: 9575118 [Abstract] [Full Text] [Related]
15. [Effect of treatment with gonadotropin releasing hormone analogues in girls with idiopathic central precocious puberty]. Ságodi L, Sólyom E, Lombay B, Almási A, Vámosi I. Orv Hetil; 2012 Mar 18; 153(11):418-24. PubMed ID: 22390866 [Abstract] [Full Text] [Related]
16. Effect of GnRHa 3.75 mg subcutaneously every 6 weeks on adult height in girls with idiopathic central precocious puberty. Liang Y, Wei H, Li J, Hou L, Zhang J, Wu W, Ying Y, Luo X. J Pediatr Endocrinol Metab; 2015 Jul 18; 28(7-8):839-46. PubMed ID: 25719299 [Abstract] [Full Text] [Related]
17. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB. J Clin Endocrinol Metab; 2001 Oct 18; 86(10):4711-6. PubMed ID: 11600530 [Abstract] [Full Text] [Related]
18. Unsustained or slowly progressive puberty in young girls: initial presentation and long-term follow-up of 20 untreated patients. Palmert MR, Malin HV, Boepple PA. J Clin Endocrinol Metab; 1999 Feb 18; 84(2):415-23. PubMed ID: 10022394 [Abstract] [Full Text] [Related]
19. GH and GnRH analog treatment in children who enter puberty at short stature. Tanaka T, Satoh M, Yasunaga T, Horikawa R, Tanae A, Hibi I. J Pediatr Endocrinol Metab; 1997 Feb 18; 10(6):623-8. PubMed ID: 9467133 [Abstract] [Full Text] [Related]
20. [The delay of bone maturation is a favorable element in the prognosis of final height]. Rochiccioli P, Tock Mine YY, Enjaume C, Dutau G, Sablayrolles B. Arch Fr Pediatr; 1985 Apr 18; 42(4):273-6. PubMed ID: 4004488 [Abstract] [Full Text] [Related] Page: [Next] [New Search]